Abstract
Programmed death ligand-1 (PD-L1) expression is a predictive biomarker guiding treatment decisions with immunotherapy in lung cancer patients, but its role in malignant pleural mesothelioma (MPM) is unclear. However, evidence suggests that higher PDL-1 expression correlates with worse survival outcomes. The Cancer and Leukemia Group B (CALGB) prognostic scoring system is widely used to define prognosis in MPM. This study aims to assess the prognostic value of PDL-1 expression integrating it into the CALGB scoring system.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
